Publications<\/p>\n
Persistent growth-promoting effects of vosoritide\u25bc\u00a0in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life\n<\/h2>\n
Savarirayan et al. assessed the impact of vosoritide on growth-associated health-related quality of life (HRQoL) in children with achondroplasia. Data were gathered using the Quality of Life in Short Stature Youth (QoLISSY) questionnaire. Vosoritide improved self-reported and caregiver-reported QoLISSY physical and social scores, with the greatest increases being seen in participants with a \u2265 1 SD increase in height Z-score\u2026<\/p>\n <\/div>\n\n
Download<\/a><\/p>\n Read More<\/a><\/p>\n <\/article>\n \n \n \n \n \n Expert Live<\/p>\n For those of you who were unable to join us for this engaging and informative case-based webinar, the recording is now available on-demand! This webinar aims to provide you with insights from leading clinicians on the practicalities of vosoritide in children <2 years of age, including multidisciplinary team management, neurological considerations within the first year of life, a real-world case study and practical support for parents and caregivers.<\/p>\n Once you have viewed the webinar, we would like to know your thoughts on the content covered by our expert faculty. Please can you take 2 minutes to complete the survey at the link below: Watch Now<\/a><\/p>\n <\/article>\n \n \n \n \n \n Podcast<\/p>\n Vosoritide in children <2 years of age: Real world experience and practical tips \u2013 Webinar\n<\/h2>\n
\nhttps:\/\/www.surveymonkey.com\/r\/RFPKPGM<\/a><\/p>\n <\/div>\n\n